Shots:

• Artios to receive $20M upfront in addition to near term research funding to support the collaboration and is eligible to receive $1.3B in discovery- development- regulatory- and sales milestones along with royalties on net sales of products
• Novartis to utilize Artios’ discovery platform to discover and validate DDR targets to enhance its radioligand therapies- selects up to three exclusive DDR targets- and will additionally receive WW rights on these targets to be used with its RLT’s
• The collaboration does not include Artios’ lead programs (ART0380 and ART4215)- currently under clinical development

  Ref: GlobeNewswire | Image: Novartis